Genetic variations in IL12B are linked to increased IBD susceptibility and disease severity (55, 56) with research indicating the potential of IL12/23p40-targeted immunotherapy for diagnosis and management, reducing invasive procedures like colonoscopy. Here, IL12B is linked to inflammatory bowel disease.